Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 3Phase 1/2 2Phase NA 1Phase 4 1Phase 2/3 1Phase 1 1

Status

Completed 4Unknown 2Terminated 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, B-Cell, Marginal Zone 1

Interventions

Exercise 27Standard of Care 24Blood Specimen Collection 18Interviews as Topic 16Educational Status 13Radiosurgery 12Drug Therapy 12Methods 11Surgical Procedures, Operative 10Surveys and Questionnaires 9Saline Solution 9Acupuncture Therapy 9Therapeutics 8Radiotherapy 8Paclitaxel 8Early Intervention, Educational 8Palliative Care 7Magnetic Resonance Spectroscopy 7Electroacupuncture 7Cryotherapy 7Specimen Handling 6Preoperative Exercise 6Practice Guidelines as Topic 6Dexmedetomidine 6Control Groups 6Colonoscopy 6Carboplatin 6tislelizumab 5Resistance Training 5Radiofrequency Ablation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Not yet recruiting × Lenalidomide × Clear all
NCT07299331 2025-12-23

Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma

Zhengzhou University

Phase NA Not yet recruiting
50 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡